Details of the Drug Combination

General Information of Drug Combination (ID: DCQHG9I)

Drug Combination Name

Sorafenib Ifosfamide

Indication

Disease Entry	Status	REF
Astrocytoma	Investigative	[1]

Component Drugs

Sorafenib DMS8IFC

Ifosfamide DMCT3I8

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: U251

Zero Interaction Potency (ZIP) Score: 5.8

Bliss Independence Score: 11.35

Loewe Additivity Score: 8.03

LHighest Single Agent (HSA) Score: 2.86

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Sorafenib

Disease Entry	ICD 11	Status	REF
Adenocarcinoma	2D40	Approved	[2]
Carcinoma	2A00-2F9Z	Approved	[2]
Clear cell renal carcinoma	N.A.	Approved	[2]
Lung cancer	2C25.0	Approved	[2]
Medullary thyroid gland carcinoma	N.A.	Approved	[2]
Non-small-cell lung cancer	2C25.Y	Approved	[2]
Renal cell carcinoma	2C90	Approved	[3]
Thyroid cancer	2D10	Approved	[2]
Hepatocellular carcinoma	2C12.02	Phase 3	[3]
Myelodysplastic syndrome	2A37	Phase 2	[3]

Sorafenib Interacts with 4 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Modulator	[11]
Platelet-derived growth factor receptor beta (PDGFRB)	TTI7421	PGFRB_HUMAN	Modulator	[11]
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[12]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Modulator	[11]
------------------------------------------------------------------------------------

Sorafenib Interacts with 7 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[13]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[14]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[15]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[16]
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[17]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[16]
RalBP1-associated Eps domain-containing protein 2 (RALBP1)	DTYEM9B	REPS2_HUMAN	Substrate	[18]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DTP(s)

Sorafenib Interacts with 6 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[19]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[20]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[21]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Metabolism	[21]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[19]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Metabolism	[22]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DME(s)

Sorafenib Interacts with 63 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Mast/stem cell growth factor receptor Kit (KIT)	OTHUY3VZ	KIT_HUMAN	Decreases Phosphorylation	[23]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Increases Expression	[24]
DNA damage-inducible transcript 4 protein (DDIT4)	OTHY8SY4	DDIT4_HUMAN	Increases Expression	[24]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[25]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Activity	[26]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Activity	[26]
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A)	OTFBU4GD	P3C2A_HUMAN	Decreases Expression	[6]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[6]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA)	OTTOMI8J	PK3CA_HUMAN	Decreases Expression	[6]
Growth factor receptor-bound protein 2 (GRB2)	OTOP7LTE	GRB2_HUMAN	Decreases Expression	[6]
Interferon regulatory factor 5 (IRF5)	OT8SIIAP	IRF5_HUMAN	Increases Expression	[6]
Serine/threonine-protein kinase PLK3 (PLK3)	OT19CT2Z	PLK3_HUMAN	Increases Expression	[6]
Serine/threonine-protein kinase PLK2 (PLK2)	OTKMJXJ8	PLK2_HUMAN	Increases Expression	[6]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[24]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Decreases Expression	[27]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Decreases Expression	[28]
Zinc finger protein SNAI2 (SNAI2)	OT7Y8EJ2	SNAI2_HUMAN	Decreases Expression	[7]
E3 ubiquitin-protein ligase parkin (PRKN)	OTJBN41W	PRKN_HUMAN	Increases Ubiquitination	[29]
Growth arrest and DNA damage-inducible protein GADD45 beta (GADD45B)	OTL9I7LO	GA45B_HUMAN	Increases Expression	[30]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A)	OTYG179K	PR15A_HUMAN	Increases Expression	[8]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G)	OT8V1J4M	GA45G_HUMAN	Increases Expression	[31]
Apoptosis-inducing factor 1, mitochondrial (AIFM1)	OTKPWB7Q	AIFM1_HUMAN	Affects Localization	[28]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Decreases Activity	[32]
RAF proto-oncogene serine/threonine-protein kinase (RAF1)	OT51LSFO	RAF1_HUMAN	Decreases Activity	[23]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Increases Expression	[30]
Tyrosine-protein kinase Lck (LCK)	OT883FG9	LCK_HUMAN	Decreases Phosphorylation	[33]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Expression	[34]
Eukaryotic translation initiation factor 4E (EIF4E)	OTDAWNLA	IF4E_HUMAN	Decreases Phosphorylation	[28]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[35]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Increases Expression	[7]
Proto-oncogene tyrosine-protein kinase Src (SRC)	OTETYX40	SRC_HUMAN	Decreases Activity	[36]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Increases Expression	[24]
G1/S-specific cyclin-D2 (CCND2)	OTDULQF9	CCND2_HUMAN	Decreases Expression	[37]
G1/S-specific cyclin-D3 (CCND3)	OTNKPQ22	CCND3_HUMAN	Decreases Expression	[38]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Decreases Phosphorylation	[39]
Mitogen-activated protein kinase 9 (MAPK9)	OTCEVJ9E	MK09_HUMAN	Decreases Phosphorylation	[39]
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4)	OTZPZX11	MP2K4_HUMAN	Decreases Phosphorylation	[39]
Crk-like protein (CRKL)	OTOYSD1R	CRKL_HUMAN	Decreases Phosphorylation	[40]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[41]
CCAAT/enhancer-binding protein delta (CEBPD)	OTNBIPMY	CEBPD_HUMAN	Increases Expression	[31]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10)	OT4PXBTA	TNF10_HUMAN	Increases Response To Substance	[42]
Gasdermin-D (GSDMD)	OTH39BKI	GSDMD_HUMAN	Increases Expression	[43]
Sestrin-2 (SESN2)	OT889IXY	SESN2_HUMAN	Increases Expression	[44]
Small ribosomal subunit protein eS6 (RPS6)	OTT4D1LN	RS6_HUMAN	Decreases Phosphorylation	[45]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Affects Localization	[46]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[28]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Decreases Expression	[47]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)	OTXEE550	APR_HUMAN	Decreases Expression	[48]
Mitogen-activated protein kinase 14 (MAPK14)	OT5TCO3O	MK14_HUMAN	Decreases Expression	[49]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Decreases Expression	[28]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Increases Expression	[9]
Docking protein 1 (DOK1)	OTGVRLW6	DOK1_HUMAN	Decreases Phosphorylation	[40]
Serine/threonine-protein kinase PINK1, mitochondrial (PINK1)	OT50NR57	PINK1_HUMAN	Increases Expression	[29]
Eukaryotic translation initiation factor 2A (EIF2A)	OTWXELQP	EIF2A_HUMAN	Increases Phosphorylation	[8]
Autophagy protein 5 (ATG5)	OT4T5SMS	ATG5_HUMAN	Increases Expression	[50]
Transcription factor SOX-17 (SOX17)	OT9H4WWE	SOX17_HUMAN	Decreases Localization	[51]
Ubiquitin carboxyl-terminal hydrolase CYLD (CYLD)	OT37FKH0	CYLD_HUMAN	Increases Expression	[52]
Diablo IAP-binding mitochondrial protein (DIABLO)	OTHJ9MCZ	DBLOH_HUMAN	Affects Localization	[48]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3)	OT0DZGY4	E2AK3_HUMAN	Increases Phosphorylation	[8]
E3 ubiquitin-protein ligase TRIM62 (TRIM62)	OT15YO6N	TRI62_HUMAN	Affects Response To Substance	[53]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Affects Response To Substance	[54]
Receptor-type tyrosine-protein kinase FLT3 (FLT3)	OTMSRYMK	FLT3_HUMAN	Increases Response To Substance	[45]
Na(+)/citrate cotransporter (SLC13A5)	OTPH1TA7	S13A5_HUMAN	Decreases Response To Substance	[55]
------------------------------------------------------------------------------------


⏷ Show the Full List of 63 DOT(s)

Indication(s) of Ifosfamide

Disease Entry	ICD 11	Status	REF
Adult central nervous system germ cell tumor	N.A.	Approved	[4]
Adult teratoma	N.A.	Approved	[4]
Advanced cancer	2A00-2F9Z	Approved	[4]
Extragonadal germ cell cancer	N.A.	Approved	[4]
Extragonadal germ cell tumor	N.A.	Approved	[4]
Kidney neoplasm	N.A.	Approved	[4]
Solid tumour/cancer	2A00-2F9Z	Approved	[5]
Testicular germ cell tumor	N.A.	Approved	[4]
Extragonadal nonseminomatous germ cell tumor	N.A.	Investigative	[4]
Extragonadal seminoma	N.A.	Investigative	[4]
Neuroblastoma	2D11.2	Investigative	[4]
Retinoblastoma	2D02.2	Investigative	[4]

Ifosfamide Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[57]
------------------------------------------------------------------------------------

Ifosfamide Interacts with 10 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[58]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Metabolism	[59]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[60]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Metabolism	[61]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Metabolism	[62]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[60]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[63]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Metabolism	[64]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[62]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Metabolism	[58]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 DME(s)

Ifosfamide Interacts with 153 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Increases Response To Substance	[65]
Alpha-2A adrenergic receptor (ADRA2A)	OTZFGOTP	ADA2A_HUMAN	Increases ADR	[66]
Solute carrier family 12 member 8 (SLC12A8)	OTHJP5FU	S12A8_HUMAN	Decreases Expression	[56]
Agrin (AGRN)	OTWJENAZ	AGRIN_HUMAN	Increases Expression	[56]
Podocalyxin (PODXL)	OTPNQXF3	PODXL_HUMAN	Decreases Expression	[56]
Class E basic helix-loop-helix protein 40 (BHLHE40)	OTITX14U	BHE40_HUMAN	Increases Expression	[56]
TRAF-type zinc finger domain-containing protein 1 (TRAFD1)	OT7AU2R3	TRAD1_HUMAN	Increases Expression	[56]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[56]
Rho guanine nucleotide exchange factor 10 (ARHGEF10)	OTHJ1Y4I	ARHGA_HUMAN	Affects Expression	[56]
Apoptosis regulatory protein Siva (SIVA1)	OTDT0XZK	SIVA_HUMAN	Increases Expression	[56]
Transcription factor MafG (MAFG)	OTBQFUZH	MAFG_HUMAN	Increases Expression	[56]
E3 ubiquitin-protein ligase SIAH2 (SIAH2)	OTKED2XN	SIAH2_HUMAN	Increases Expression	[56]
Protein regulator of cytokinesis 1 (PRC1)	OTHD0XS0	PRC1_HUMAN	Increases Expression	[56]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1)	OTEAUJXN	TRIA1_HUMAN	Increases Expression	[56]
5'-AMP-activated protein kinase subunit beta-2 (PRKAB2)	OTLVN68B	AAKB2_HUMAN	Affects Expression	[56]
Mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20)	OT6CLFXB	MCAT_HUMAN	Increases Expression	[56]
NUAK family SNF1-like kinase 1 (NUAK1)	OTLLHJJQ	NUAK1_HUMAN	Decreases Expression	[56]
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A (PDE8A)	OT4RF9Z4	PDE8A_HUMAN	Decreases Expression	[56]
Mitochondrial import inner membrane translocase subunit Tim17-B (TIMM17B)	OTSQGLSB	TI17B_HUMAN	Decreases Expression	[56]
PR domain zinc finger protein 1 (PRDM1)	OTQLSVBS	PRDM1_HUMAN	Decreases Expression	[56]
E3 ubiquitin-protein ligase listerin (LTN1)	OTIW2HTX	LTN1_HUMAN	Decreases Expression	[56]
Tumor necrosis factor alpha-induced protein 8 (TNFAIP8)	OT1G9297	TFIP8_HUMAN	Increases Expression	[56]
Tetraspanin-12 (TSPAN12)	OTF9I3CX	TSN12_HUMAN	Decreases Expression	[56]
Fructose-bisphosphate aldolase A (ALDOA)	OTWRFTIB	ALDOA_HUMAN	Increases Expression	[56]
Fatty acid-binding protein, heart (FABP3)	OT562DA1	FABPH_HUMAN	Decreases Expression	[56]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Decreases Expression	[56]
Glycogen phosphorylase, liver form (PYGL)	OTS1YFGR	PYGL_HUMAN	Decreases Expression	[56]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Increases Expression	[56]
Gamma-enolase (ENO2)	OTRODL0T	ENOG_HUMAN	Increases Expression	[56]
RNA-binding protein RO60 (RO60)	OTLGM5A8	RO60_HUMAN	Decreases Expression	[56]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)	OTA675TJ	GTR1_HUMAN	Increases Expression	[56]
Cation-independent mannose-6-phosphate receptor (IGF2R)	OTDXPQVX	MPRI_HUMAN	Increases Expression	[56]
Protein SON (SON)	OT9VWV18	SON_HUMAN	Decreases Expression	[56]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Affects Activity	[56]
Keratin, type I cytoskeletal 15 (KRT15)	OTS6WLF7	K1C15_HUMAN	Increases Expression	[56]
Ephrin-A1 (EFNA1)	OTU2NUA2	EFNA1_HUMAN	Decreases Expression	[56]
Ferrochelatase, mitochondrial (FECH)	OTDWEI6C	HEMH_HUMAN	Decreases Expression	[56]
Diacylglycerol kinase alpha (DGKA)	OTTBVNEZ	DGKA_HUMAN	Increases Expression	[56]
DnaJ homolog subfamily B member 2 (DNAJB2)	OTZHPV5M	DNJB2_HUMAN	Increases Expression	[56]
Threonine--tRNA ligase 1, cytoplasmic (TARS1)	OT0PWST5	SYTC_HUMAN	Decreases Expression	[56]
Adenylate kinase 4, mitochondrial (AK4)	OTA0T02Q	KAD4_HUMAN	Increases Expression	[56]
ETS domain-containing protein Elk-4 (ELK4)	OTVSSEOE	ELK4_HUMAN	Decreases Expression	[56]
Tyrosine-protein kinase receptor UFO (AXL)	OTKA2SUX	UFO_HUMAN	Increases Expression	[56]
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Increases Expression	[56]
Pyrroline-5-carboxylate reductase 1, mitochondrial (PYCR1)	OTQHB52T	P5CR1_HUMAN	Increases Expression	[56]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1)	OTB06ESI	ACSL1_HUMAN	Decreases Expression	[56]
Thrombospondin-2 (THBS2)	OTXET551	TSP2_HUMAN	Decreases Expression	[56]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Increases Expression	[56]
Transaldolase (TALDO1)	OTDKV2S2	TALDO_HUMAN	Increases Expression	[56]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[56]
Glycine--tRNA ligase (GARS1)	OT5B6R9Y	GARS_HUMAN	Increases Expression	[56]
Isoleucine--tRNA ligase, cytoplasmic (IARS1)	OT9WXH5N	SYIC_HUMAN	Increases Expression	[56]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9)	OTV9L89D	TNFL9_HUMAN	Increases Expression	[56]
Eukaryotic translation initiation factor 1 (EIF1)	OTB4GZ0V	EIF1_HUMAN	Increases Expression	[56]
Retinaldehyde dehydrogenase 3 (ALDH1A3)	OT1C9NKQ	AL1A3_HUMAN	Increases Expression	[56]
Cysteine--tRNA ligase, cytoplasmic (CARS1)	OTOUZF6O	SYCC_HUMAN	Decreases Expression	[56]
Serine--tRNA ligase, cytoplasmic (SARS1)	OTFKXQ1O	SYSC_HUMAN	Increases Expression	[56]
Max-interacting protein 1 (MXI1)	OTUQ9E0D	MXI1_HUMAN	Decreases Expression	[56]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Increases Expression	[56]
Ataxin-1 (ATXN1)	OTQF0HNR	ATX1_HUMAN	Decreases Expression	[56]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1)	OTYHXLWZ	BCAT1_HUMAN	Decreases Expression	[56]
Homeobox protein DLX-1 (DLX1)	OT7BH057	DLX1_HUMAN	Decreases Expression	[56]
Protein BTG2 (BTG2)	OTZF6K1H	BTG2_HUMAN	Increases Expression	[56]
Large neutral amino acids transporter small subunit 1 (SLC7A5)	OT2WPVXD	LAT1_HUMAN	Increases Expression	[56]
Transmembrane protein 94 (TMEM94)	OTT4ZSUA	TMM94_HUMAN	Decreases Expression	[56]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)	OT4SO7J4	BNIP3_HUMAN	Decreases Expression	[56]
Zinc finger protein Rlf (RLF)	OTCSPZVK	RLF_HUMAN	Increases Expression	[56]
Peptidyl-prolyl cis-trans isomerase G (PPIG)	OTZ8BTTM	PPIG_HUMAN	Decreases Expression	[56]
Ras-related protein Rab-31 (RAB31)	OTMLXQZ0	RAB31_HUMAN	Increases Expression	[56]
Kelch-like ECH-associated protein 1 (KEAP1)	OTFHOD0C	KEAP1_HUMAN	Increases Expression	[56]
Src substrate cortactin (CTTN)	OTJRG4ES	SRC8_HUMAN	Increases Expression	[56]
Protein disulfide-isomerase A5 (PDIA5)	OT76ZSX5	PDIA5_HUMAN	Increases Expression	[56]
Condensin complex subunit 1 (NCAPD2)	OT8VGE2O	CND1_HUMAN	Increases Expression	[56]
Probable E3 ubiquitin-protein ligase HERC3 (HERC3)	OTWMKYD9	HERC3_HUMAN	Decreases Expression	[56]
kinase isozyme 1, mitochondrial (PDK1)	OTMABK9Z	PDK1_HUMAN	Decreases Expression	[56]
Neutral amino acid transporter B(0) (SLC1A5)	OTE2H26Q	AAAT_HUMAN	Increases Expression	[56]
Cyclin-G2 (CCNG2)	OTII38K2	CCNG2_HUMAN	Decreases Expression	[56]
Neuronal regeneration-related protein (NREP)	OT2AZPKK	NREP_HUMAN	Affects Expression	[56]
Laminin subunit alpha-3 (LAMA3)	OTFME7HT	LAMA3_HUMAN	Increases Expression	[56]
Atos homolog protein A (ATOSA)	OTWFM5G0	ATOSA_HUMAN	Decreases Expression	[56]
Glycerol-3-phosphate acyltransferase 3 (GPAT3)	OTJUGPK0	GPAT3_HUMAN	Increases Expression	[56]
Quinone oxidoreductase PIG3 (TP53I3)	OTSCM68G	QORX_HUMAN	Increases Expression	[56]
RRP12-like protein (RRP12)	OTQQAEH4	RRP12_HUMAN	Increases Expression	[56]
ALS2 C-terminal-like protein (ALS2CL)	OT8RY7TZ	AL2CL_HUMAN	Affects Expression	[56]
Dynamin-binding protein (DNMBP)	OTMHH14H	DNMBP_HUMAN	Increases Expression	[56]
Ribosomal protein eS27-like (RPS27L)	OTZWHU0N	RS27L_HUMAN	Increases Expression	[56]
Arginine/serine-rich coiled-coil protein 2 (RSRC2)	OTLE0KQM	RSRC2_HUMAN	Decreases Expression	[56]
Mitochondrial enolase superfamily member 1 (ENOSF1)	OT65D3ZK	ENOF1_HUMAN	Decreases Expression	[56]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B)	OTE8GBUR	RIR2B_HUMAN	Decreases Expression	[56]
Protein LYRIC (MTDH)	OTGH7N4C	LYRIC_HUMAN	Decreases Expression	[56]
Liprin-beta-1 (PPFIBP1)	OTRA2S7B	LIPB1_HUMAN	Increases Expression	[56]
Dynein axonemal intermediate chain 3 (DNAI3)	OTG1A0QP	DNAI3_HUMAN	Decreases Expression	[56]
Protein O-mannosyl-transferase TMTC2 (TMTC2)	OTY1QWYU	TMTC2_HUMAN	Decreases Expression	[56]
Ninein (NIN)	OTVH3M4Z	NIN_HUMAN	Decreases Expression	[56]
Ceramide synthase 5 (CERS5)	OT5A2DNI	CERS5_HUMAN	Increases Expression	[56]
Uncharacterized protein C8orf58 (C8ORF58)	OTHW01L0	CH058_HUMAN	Increases Expression	[56]
F-box only protein 22 (FBXO22)	OTEJ5MO0	FBX22_HUMAN	Increases Expression	[56]
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4)	OTQK3M9X	ABHD4_HUMAN	Increases Expression	[56]
F-box only protein 30 (FBXO30)	OTD1P6LA	FBX30_HUMAN	Decreases Expression	[56]
Pantothenate kinase 1 (PANK1)	OT2CZVRT	PANK1_HUMAN	Decreases Expression	[56]
SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1)	OT0HYZIU	S3TC1_HUMAN	Decreases Expression	[56]
Uncharacterized protein C4orf3 (C4ORF3)	OT6TFN1O	CD003_HUMAN	Decreases Expression	[56]
Paraspeckle component 1 (PSPC1)	OTYS6WQ8	PSPC1_HUMAN	Decreases Expression	[56]
E3 ubiquitin-protein ligase rififylin (RFFL)	OT85MGDH	RFFL_HUMAN	Increases Expression	[56]
Probable ATP-dependent RNA helicase DDX17 (DDX17)	OTXRMMBP	DDX17_HUMAN	Decreases Expression	[56]
GTP-binding protein Rit1 (RIT1)	OTVNOGOH	RIT1_HUMAN	Increases Expression	[56]
KICSTOR complex protein ITFG2 (ITFG2)	OT0NLZ8I	ITFG2_HUMAN	Decreases Expression	[56]
Protein TMEPAI (PMEPA1)	OTY8Z9UF	PMEPA_HUMAN	Increases Expression	[56]
Protein FAM162A (FAM162A)	OT882DND	F162A_HUMAN	Decreases Expression	[56]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1)	OT2363Z9	T53I1_HUMAN	Increases Expression	[56]
SPRY domain-containing SOCS box protein 1 (SPSB1)	OTGY26U4	SPSB1_HUMAN	Increases Expression	[56]
Carboxymethylenebutenolidase homolog (CMBL)	OT8H3S3G	CMBL_HUMAN	Increases Expression	[56]
Protein FAM89A (FAM89A)	OTNASAXT	FA89A_HUMAN	Increases Expression	[56]
ERO1-like protein alpha (ERO1A)	OTVKOQWM	ERO1A_HUMAN	Increases Expression	[56]
Protein FAM210B, mitochondrial (FAM210B)	OT2QHEQ6	F210B_HUMAN	Decreases Expression	[56]
E1A-binding protein p400 (EP400)	OTVQ75NX	EP400_HUMAN	Decreases Expression	[56]
Calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2)	OT9C3KFI	KKCC2_HUMAN	Increases Expression	[56]
ETS-related transcription factor Elf-4 (ELF4)	OT167PR5	ELF4_HUMAN	Increases Expression	[56]
Eukaryotic translation initiation factor 3 subunit C (EIF3C)	OTR8RF9X	EIF3C_HUMAN	Decreases Expression	[56]
Cancer-related nucleoside-triphosphatase (NTPCR)	OTTRT6Z9	NTPCR_HUMAN	Increases Expression	[56]
Sulfiredoxin-1 (SRXN1)	OTYDBO4L	SRXN1_HUMAN	Increases Expression	[56]
G protein-coupled receptor 88 (GPR88)	OTGAT70V	GPR88_HUMAN	Increases Expression	[56]
Coiled-coil domain-containing protein 90B, mitochondrial (CCDC90B)	OTFFWB0C	CC90B_HUMAN	Decreases Expression	[56]
Polyprenol reductase (SRD5A3)	OT9IJLX7	PORED_HUMAN	Decreases Expression	[56]
E3 ubiquitin ligase RNF121 (RNF121)	OTA0YMLW	RN121_HUMAN	Decreases Expression	[56]
Ankyrin repeat family A protein 2 (ANKRA2)	OTLSLV5A	ANRA2_HUMAN	Decreases Expression	[56]
p53-induced death domain-containing protein 1 (PIDD1)	OTWFM930	PIDD1_HUMAN	Decreases Expression	[56]
ABC-type oligopeptide transporter ABCB9 (ABCB9)	OTSOBOL5	ABCB9_HUMAN	Increases Expression	[56]
Fructose-2,6-bisphosphatase TIGAR (TIGAR)	OTR7NMRJ	TIGAR_HUMAN	Increases Expression	[56]
Dual specificity protein phosphatase 22 (DUSP22)	OTEZ3U85	DUS22_HUMAN	Increases Expression	[56]
PAK4-inhibitor INKA2 (INKA2)	OT9RA64U	INKA2_HUMAN	Increases Expression	[56]
DNA damage-inducible transcript 4 protein (DDIT4)	OTHY8SY4	DDIT4_HUMAN	Increases Expression	[56]
LIM and cysteine-rich domains protein 1 (LMCD1)	OT3AWE8O	LMCD1_HUMAN	Decreases Expression	[56]
Signal-induced proliferation-associated 1-like protein 2 (SIPA1L2)	OT8NJE5D	SI1L2_HUMAN	Decreases Expression	[56]
Dolichol-phosphate mannosyltransferase subunit 3 (DPM3)	OTSB4XO0	DPM3_HUMAN	Increases Expression	[56]
DnaJ homolog subfamily B member 9 (DNAJB9)	OT38EQT6	DNJB9_HUMAN	Increases Expression	[56]
Mitochondrial fission process protein 1 (MTFP1)	OT3L6F7U	MTFP1_HUMAN	Increases Expression	[56]
SERTA domain-containing protein 1 (SERTAD1)	OTBHKZQP	SRTD1_HUMAN	Increases Expression	[56]
Oxidative stress-induced growth inhibitor 1 (OSGIN1)	OT9KIVZW	OSGI1_HUMAN	Decreases Expression	[56]
Heme transporter FLVCR2 (FLVCR2)	OTAM94ID	FLVC2_HUMAN	Decreases Expression	[56]
Exocyst complex component 7 (EXOC7)	OT4YA137	EXOC7_HUMAN	Increases Expression	[56]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)	OT1OG4QZ	AAKB1_HUMAN	Affects Expression	[56]
RNA polymerase II subunit A C-terminal domain phosphatase (CTDP1)	OTHHFW17	CTDP1_HUMAN	Decreases Expression	[56]
Pleckstrin homology-like domain family A member 3 (PHLDA3)	OTXFUDO2	PHLA3_HUMAN	Increases Expression	[56]
Insulin-induced gene 2 protein (INSIG2)	OTX4VY51	INSI2_HUMAN	Increases Expression	[56]
Sestrin-1 (SESN1)	OTSFDZWL	SESN1_HUMAN	Increases Expression	[56]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Increases Activity	[67]
Osteocalcin (BGLAP)	OTK1YLWQ	OSTCN_HUMAN	Decreases Expression	[68]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[67]
HLA class I histocompatibility antigen, alpha chain G (HLA-G)	OTMLK1KN	HLAG_HUMAN	Affects Expression	[69]
Glutathione peroxidase 3 (GPX3)	OT6PK94R	GPX3_HUMAN	Decreases Activity	[70]
Major histocompatibility complex class I-related gene protein (MR1)	OTZU3XX7	HMR1_HUMAN	Affects Expression	[69]
Elastin (ELN)	OTFSO7PG	ELN_HUMAN	Increases ADR	[66]
------------------------------------------------------------------------------------


⏷ Show the Full List of 153 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCQUZ1P	DU-145	Investigative	[1]
Adenocarcinoma	DCW119E	HT29	Investigative	[1]
Adult acute myeloid leukemia	DCGAWOL	HL-60(TB)	Investigative	[1]
Amelanotic melanoma	DC1YYXO	M14	Investigative	[1]
Childhood T acute lymphoblastic leukemia	DC54GUG	CCRF-CEM	Investigative	[1]
Chronic myelogenous leukemia	DCMPMMC	K-562	Investigative	[1]
Cutaneous melanoma	DCRY6KV	SK-MEL-28	Investigative	[1]
Lung adenocarcinoma	DC2YBAY	HOP-62	Investigative	[1]
Lung adenocarcinoma	DCUWO09	MDA-MB-231	Investigative	[1]
Lung adenocarcinoma	DCAU2GZ	NCI-H522	Investigative	[1]
Melanoma	DCS1GO4	SK-MEL-2	Investigative	[1]
Melanoma	DC4YAVH	UACC-257	Investigative	[1]
Minimally invasive lung adenocarcinoma	DCY7Y44	NCI-H322M	Investigative	[1]
Ovarian serous cystadenocarcinoma	DCNUSBV	SK-OV-3	Investigative	[1]
Plasma cell myeloma	DCF0MYT	RPMI-8226	Investigative	[1]
Invasive ductal carcinoma	DCUI0XG	HS 578T	Investigative	[71]
------------------------------------------------------------------------------------


⏷ Show the Full List of 16 DrugCom(s)

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2	Sorafenib FDA Label
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
4	Ifosfamide FDA Label
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7201).
6	Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015 Dec 5;242:107-22.
7	Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/-catenin signaling pathway and epithelial-mesenchymal transition. Toxicol In Vitro. 2014 Jun;28(4):552-61. doi: 10.1016/j.tiv.2014.01.002. Epub 2014 Jan 13.
8	The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol. 2007 Aug;27(15):5499-513. doi: 10.1128/MCB.01080-06. Epub 2007 Jun 4.
9	Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008 Apr;22(4):808-18. doi: 10.1038/sj.leu.2405098. Epub 2008 Jan 17.
10	Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. Toxicol In Vitro. 2018 Sep;51:74-82. doi: 10.1016/j.tiv.2018.04.010. Epub 2018 Apr 24.
11	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
12	Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
13	Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
14	Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26.
15	Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
16	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
17	Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
18	Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
19	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
20	Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
21	Drug Interactions Flockhart Table
22	Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
23	Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Jan;8(1):152-9. doi: 10.1158/1535-7163.MCT-08-0553.
24	Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. Biochem Pharmacol. 2011 Aug 1;82(3):216-26. doi: 10.1016/j.bcp.2011.04.011. Epub 2011 May 13.
25	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
26	Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer. 2012 Sep 10;12:402.
27	The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007 Oct 1;67(19):9490-500. doi: 10.1158/0008-5472.CAN-07-0598.
28	Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005 Oct 21;280(42):35217-27. doi: 10.1074/jbc.M506551200. Epub 2005 Aug 18.
29	Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. J Biol Chem. 2017 Sep 8;292(36):15105-15120. doi: 10.1074/jbc.M117.783175. Epub 2017 Jul 3.
30	Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010 Nov 15;70(22):9309-18. doi: 10.1158/0008-5472.CAN-10-1033. Epub 2010 Nov 9.
31	Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. Oncotarget. 2015 Sep 29;6(29):27953-65. doi: 10.18632/oncotarget.4446.
32	Sorafenib inhibits transforming growth factor 1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology. 2011 May;53(5):1708-18. doi: 10.1002/hep.24254.
33	Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.
34	Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007 Oct 1;67(19):9443-54. doi: 10.1158/0008-5472.CAN-07-1473.
35	Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat. 2010 Nov;124(1):79-88. doi: 10.1007/s10549-009-0714-5. Epub 2010 Jan 7.
36	Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anticancer Drugs. 2011 Jan;22(1):79-88. doi: 10.1097/CAD.0b013e32833f44fd.
37	Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther. 2008 Nov;7(11):3519-26. doi: 10.1158/1535-7163.MCT-08-0138.
38	Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80. doi: 10.1124/jpet.106.108621. Epub 2006 Sep 7.
39	Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression. Environ Toxicol. 2018 Dec;33(12):1237-1244. doi: 10.1002/tox.22630. Epub 2018 Sep 6.
40	Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
41	Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer. 2009 Oct 31;9:387. doi: 10.1186/1471-2407-9-387.
42	The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer. 2010 Mar;46(4):836-50. doi: 10.1016/j.ejca.2009.12.025. Epub 2010 Jan 12.
43	Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. Toxicol In Vitro. 2021 Mar;71:105063. doi: 10.1016/j.tiv.2020.105063. Epub 2020 Dec 1.
44	Protective effect of sestrin2 against iron overload and ferroptosis-induced liver injury. Toxicol Appl Pharmacol. 2019 Sep 15;379:114665. doi: 10.1016/j.taap.2019.114665. Epub 2019 Jul 16.
45	Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett. 2013 Feb 1;329(1):45-58. doi: 10.1016/j.canlet.2012.09.020. Epub 2012 Oct 2.
46	The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005 Oct 20;24(46):6861-9. doi: 10.1038/sj.onc.1208841.
47	The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J Androl. 2010 Jul;12(4):527-34. doi: 10.1038/aja.2010.21. Epub 2010 May 17.
48	GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem. 2008 Jan 11;283(2):726-32. doi: 10.1074/jbc.M705343200. Epub 2007 Nov 8.
49	Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther. 2006 Sep;5(9):2378-87. doi: 10.1158/1535-7163.MCT-06-0235.
50	Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther. 2008 Oct;7(10):1648-62. doi: 10.4161/cbt.7.10.6623. Epub 2008 Oct 12.
51	A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
52	Down-regulation of CYLD as a trigger for NF-B activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J Oncol. 2011 Jan;38(1):121-31.
53	TRIM62 silencing represses the proliferation and invasion and increases the chemosensitivity of hepatocellular carcinoma cells by affecting the NF-B pathway. Toxicol Appl Pharmacol. 2022 Jun 15;445:116035. doi: 10.1016/j.taap.2022.116035. Epub 2022 Apr 23.
54	The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One. 2013 Nov 11;8(11):e78675. doi: 10.1371/journal.pone.0078675. eCollection 2013.
55	Comparative proteomic analysis of SLC13A5 knockdown reveals elevated ketogenesis and enhanced cellular toxic response to chemotherapeutic agents in HepG2 cells. Toxicol Appl Pharmacol. 2020 Sep 1;402:115117. doi: 10.1016/j.taap.2020.115117. Epub 2020 Jul 4.
56	Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
57	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
58	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
59	Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
60	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
61	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
62	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
63	CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
64	A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem. 2003 Apr 18;278(16):14146-52.
65	Advantages of human hepatocyte-derived transformants expressing a series of human cytochrome p450 isoforms for genotoxicity examination. Toxicol Sci. 2010 Aug;116(2):488-97. doi: 10.1093/toxsci/kfq154. Epub 2010 May 27.
66	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
67	PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
68	Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide. In Vivo. 1992 Mar-Apr;6(2):219-21.
69	Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
70	Plasma glutathione peroxidase and its relationship to renal proximal tubule function. Mol Genet Metab. 1998 Nov;65(3):238-45. doi: 10.1006/mgme.1998.2760.
71	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165